EA201070609A1 - Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств - Google Patents

Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств

Info

Publication number
EA201070609A1
EA201070609A1 EA201070609A EA201070609A EA201070609A1 EA 201070609 A1 EA201070609 A1 EA 201070609A1 EA 201070609 A EA201070609 A EA 201070609A EA 201070609 A EA201070609 A EA 201070609A EA 201070609 A1 EA201070609 A1 EA 201070609A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obesity
methods
disorders
diseases
treating
Prior art date
Application number
EA201070609A
Other languages
English (en)
Inventor
Джонатан Дэвид Рот
Ален Д. Бэрон
Кристен Андерсон
Original Assignee
Амилин Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амилин Фармасьютикалз, Инк. filed Critical Амилин Фармасьютикалз, Инк.
Publication of EA201070609A1 publication Critical patent/EA201070609A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Раскрыты способы лечения ожирения или ассоциированных с ожирением расстройств. Эти способы включают применение агентов против ожирения, направленных на передний мозг, в комбинации с агентами против ожирения, направленными на задний мозг.
EA201070609A 2007-11-14 2007-11-14 Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств EA201070609A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/084733 WO2009064298A1 (en) 2007-11-14 2007-11-14 Methods for treating obesity and obesity related diseases and disorders

Publications (1)

Publication Number Publication Date
EA201070609A1 true EA201070609A1 (ru) 2010-12-30

Family

ID=39642692

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070609A EA201070609A1 (ru) 2007-11-14 2007-11-14 Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств

Country Status (16)

Country Link
US (1) US20100323955A1 (ru)
EP (1) EP2219664A1 (ru)
JP (1) JP2011503180A (ru)
KR (1) KR20100098628A (ru)
CN (1) CN101939022A (ru)
AU (1) AU2007360979B2 (ru)
BR (1) BRPI0722276A2 (ru)
CA (1) CA2705708A1 (ru)
EA (1) EA201070609A1 (ru)
IL (1) IL205730A0 (ru)
MA (1) MA31842B1 (ru)
MX (1) MX2010005345A (ru)
TN (1) TN2010000214A1 (ru)
UA (1) UA97707C2 (ru)
WO (1) WO2009064298A1 (ru)
ZA (1) ZA201003497B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024507B1 (ru) 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
EP2714069A4 (en) * 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
KR102052983B1 (ko) 2012-01-26 2019-12-06 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
CA2886393C (en) * 2012-09-27 2019-02-26 The Children's Medical Center Corporation Pentacyclic triterpenes for the treatment of obesity
JP6538682B2 (ja) 2013-07-30 2019-07-03 ソアレス クリストファー ジェイ． Ｃｇｒｐアゴニストペプチド
WO2017082946A1 (en) * 2015-11-13 2017-05-18 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
US10775386B2 (en) 2016-09-12 2020-09-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
CN106749524B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖七肽npvwkrk
EP4360651A2 (en) 2017-08-24 2024-05-01 Novo Nordisk A/S Glp-1 compositions and uses thereof
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
EP4106724A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2022248419A2 (en) * 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4091625A1 (en) * 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) * 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
EP0717635B1 (en) * 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5856098A (en) * 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997029079A1 (fr) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2001500869A (ja) * 1996-09-20 2001-01-23 ヘキスト、アクチェンゲゼルシャフト 第ｉｉ種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用
US6180653B1 (en) * 1996-12-16 2001-01-30 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
ATE304864T1 (de) * 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
SI0966436T1 (en) * 1997-02-21 2003-04-30 Bayer Aktiengesellschaft Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
WO1998047505A1 (fr) * 1997-04-23 1998-10-29 Banyu Pharmaceutical Co., Ltd. Antagoniste de recepteur de neuropeptide y
US6001836A (en) * 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
WO1999055667A1 (en) * 1998-04-29 1999-11-04 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
WO2000025806A1 (en) * 1998-11-04 2000-05-11 Aronne Louis J Method for weight control
AU756797B2 (en) * 1998-11-10 2003-01-23 Banyu Pharmaceutical Co., Ltd. Spiro-indolines as Y5 receptor antagonists
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CZ20013278A3 (cs) * 1999-03-19 2002-07-17 Knoll Gmbh Pouľití sloučeniny a farmaceutická kompozice ji obsahující
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6124331A (en) * 1999-06-30 2000-09-26 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6340683B1 (en) * 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6214853B1 (en) * 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
DE19949319A1 (de) * 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
EP1264826B1 (en) * 2000-02-22 2005-03-30 Banyu Pharmaceutical Co., Ltd. Novel imidazoline compounds
US6930185B2 (en) * 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6686337B2 (en) * 2000-10-30 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
GB0105069D0 (en) * 2001-03-01 2001-04-18 Univ Ulster The Modified peptide
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
CA2492225A1 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
US7141561B2 (en) * 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005033137A1 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
AU2004309368A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20090156474A1 (en) * 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders

Also Published As

Publication number Publication date
EP2219664A1 (en) 2010-08-25
IL205730A0 (en) 2010-11-30
MX2010005345A (es) 2010-08-31
AU2007360979A2 (en) 2010-07-15
TN2010000214A1 (en) 2011-11-11
CA2705708A1 (en) 2009-05-22
CN101939022A (zh) 2011-01-05
ZA201003497B (en) 2011-02-23
JP2011503180A (ja) 2011-01-27
US20100323955A1 (en) 2010-12-23
KR20100098628A (ko) 2010-09-08
BRPI0722276A2 (pt) 2014-04-22
AU2007360979B2 (en) 2014-04-10
UA97707C2 (ru) 2012-03-12
AU2007360979A1 (en) 2009-05-22
WO2009064298A1 (en) 2009-05-22
MA31842B1 (fr) 2010-11-01

Similar Documents

Publication Publication Date Title
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
DK1814590T4 (da) Behandling af obesitet og beslægtede sygdomme.
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2020009403A (es) Compuestos con actividad anticancer.
ATE476418T1 (de) Benzamidderivate und assoziierte verwendungen
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
IL215579A0 (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
IL207277A0 (en) Novel 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, cx3cr1 and p40
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
WO2007055743A3 (en) Treatment of obesity and related disorders
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
EA201000433A1 (ru) Лечение вазомоторных симптомов
EA201000864A1 (ru) Фенилоксетанильные производные
CY1121275T1 (el) Θεραπεια των διαταραχων του εθισμου και του ελεγχου της παρορμητικοτητας χρησιμοποιωντας αναστολεις pde7
ECSP10010250A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad
DOP2010000147A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad